Patents Examined by Shanon A. Foley
  • Patent number: 10729756
    Abstract: Multiple DIVA vaccines effective against porcine reproductive and respiratory syndrome virus (PRRSV) are disclosed. The DIVA vaccines may be negative DIVAs or positive DIVAs. The DIVA vaccines may be produced by modifying the nsp2 region of a modified live virus vaccine. The modification may be one or more deletions only (negative DIVAs) or a deletion with an insertion (positive DIVAs). The insertion may be of an epitope tag, such as a V5, S-Tag, or FLAG tag. Produced DIVA vaccines may be stable through multiple passes and thus may be effective for production and vaccination of animals.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: August 4, 2020
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Kay S. Faaberg, Allyn Spear, Matthew A. Kappes, Kelly M. Lager
  • Patent number: 10729760
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 4, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 10729757
    Abstract: Novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof are described, and the pre-fusion RSV F protein contains the amino acid sequence of SEQ ID NO: 1 or 2. Use of the nucleic acid molecules, or vectors containing the nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV) is also described.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: August 4, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Janneke M. Verhagen
  • Patent number: 10717967
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 21, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Patent number: 10711254
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 14, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Patent number: 10711255
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 14, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Patent number: 10703781
    Abstract: The present invention relates to a piscine myocarditis virus (PMCV) virus-like particle (VLP) which consists only of PMCV ORF1 protein.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: July 7, 2020
    Assignee: PHARMAQ AS
    Inventors: Pal Nilsen, Marit Rode
  • Patent number: 10704028
    Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 7, 2020
    Assignee: CEVA SANTE ANIMALE
    Inventors: Saeki Yukari, Shuji Saitoh
  • Patent number: 10689437
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 23, 2020
    Assignee: MedImmune, LLC
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Patent number: 10689434
    Abstract: The invention provides an antibody (in particular, a humanized antibody) against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a method for preparing the same, and a pharmaceutical composition comprising the same. The invention also provides use of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition according to the invention can be used for preventing and/or treating HBV infection or a disease associated with HBV infection (such as Hepatitis B), for neutralizing HBV virulence in a subject (such as human), or for reducing the serum level of HBV DNA and/or HBsAg in a subject.
    Type: Grant
    Filed: October 9, 2016
    Date of Patent: June 23, 2020
    Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.
    Inventors: Wenxin Luo, Bing Zhou, Juan Zhang, Quan Yuan, Tianying Zhang, Jun Zhang, Ningshao Xia
  • Patent number: 10683343
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 16, 2020
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
  • Patent number: 10668139
    Abstract: This invention provides a protein-A or protein-G treated Mycoplasma hyopneumoniae (M.hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M.hyo antigen is an M.hyo culture supernatant.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: June 2, 2020
    Assignee: Zoetis Services LLC
    Inventors: Jeffrey E. Galvin, Gregory P. Nitzel, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 10668145
    Abstract: This invention provides a combination of a first vaccine comprising a porcine circovirus type 2 (PCV2) antigen and a Mycoplasma hyopneumoniae (M. hyo) culture supernatant and a second vaccine comprising a porcine reproductive and respiratory syndrome (PRRS) virus antigen, for treating an animal against an infection with PCV2, an infection with M. hyo, and an infection with PRRS virus, wherein the M. hyo culture supernatant has been separated from insoluble cellular material and is substantially free of both IgG and immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: June 2, 2020
    Assignee: Zoetis Services LLC
    Inventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 10660952
    Abstract: The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 26, 2020
    Inventors: Troy James Kaiser, Jeremy Kroll, Eric Martin Vaughn
  • Patent number: 10660947
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: May 26, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty
  • Patent number: 10654898
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: May 19, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Serices
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Patent number: 10646438
    Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: May 12, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria A. Croyle, Jin Huk Choi, Stephen Clay Schafer
  • Patent number: 10646557
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: May 12, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty
  • Patent number: 10639364
    Abstract: The present invention belongs to the field of animal health and provides means to study Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and for the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS. In a first consideration, the invention relates to a new PRRS virus variant. and, in a second consideration, to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone. Based on this, new PRRS vaccine candidates with improved properties are provided.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 5, 2020
    Inventors: Andreas Gallei, Christoph Keller, Erik Schacht, Marieke Herrel
  • Patent number: 10633637
    Abstract: The present invention relates to a vaccine for protecting a piglet against diseases associated with a novel pestivirus. The vaccine commonly includes a pestivirus antigen and, optionally an adjuvant. Methods for protecting pigs against diseases associated with pestivirus, including but not limited to congenital tremors and methods of producing the pestivirus vaccine are also provided.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: April 28, 2020
    Assignees: Boehringer Ingelheim Vetmedica GmbH, Iowa State University Research Foundation, Inc.
    Inventors: Joseph Gilbert Victoria, Abby Rae Patterson, Callie Ann Visek, Arun V. Iyer, Lea Ann Hobbs, Bailey Lauren Arruda, Paulo Henrique Elias Arruda, Drew Robert Magstadt, Kent Jay Schwartz